PA
AXSM icon

Perceptive Advisors’s Axsome Therapeutics AXSM Stock Holding History

Perceptive Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29M Sell
118,450
-31,500
-21% -$6.83M 0.44% 47
2026
Q1 		$25.3M Buy
149,950
+1,050
+0.7% +$181K 0.5% 44
2025
Q4 		$27.2M Hold
148,900
– – 0.48% 52
2025
Q3 		$18.1M Sell
148,900
-49,634
-25% -$5.59M 0.52% 47
2025
Q2 		$20.7M Sell
198,534
-156,573
-44% -$16.6M 0.77% 36
2025
Q1 		$41.4M Sell
355,107
-308,967
-47% -$35.2M 1.46% 20
2024
Q4 		$56.2M Sell
664,074
-118,770
-15% -$10.9M 1.55% 20
2024
Q3 		$70.4M Buy
782,844
+323,733
+71% +$28.3M 1.49% 19
2024
Q2 		$37M Sell
459,111
-646,230
-58% -$47.8M 0.89% 32
2024
Q1 		$88.2M Buy
1,105,341
+67,322
+6% +$5.65M 1.54% 21
2023
Q4 		$82.6M Buy
1,038,019
+556,370
+116% +$37.2M 1.84% 12
2023
Q3 		$33.7M Buy
481,649
+210,156
+77% +$15.7M 1.12% 28
2023
Q2 		$19.5M Buy
+271,493
New +$20M 0.56% 51
2022
Q1 		– Sell
-80,420
Closed -$3.04M – 137
2021
Q4 		$3.04M Hold
80,420
– – 0.05% 129
2021
Q3 		$2.65M Sell
80,420
-473,488
-85% -$18.5M 0.04% 129
2021
Q2 		$37.4M Buy
+553,908
New +$33.2M 0.48% 52
2020
Q3 		– Sell
-50,000
Closed -$4.11M – 132
2020
Q2 		$4.11M Buy
+50,000
New +$3.85M 0.07% 97
2019
Q4 		– Sell
-53,879
Closed -$1.09M – 116
2019
Q3 		$1.09M Hold
53,879
– – 0.03% 87
2019
Q2 		$1.39M Hold
53,879
– – 0.03% 88
2019
Q1 		$767K Buy
+53,879
New +$500K 0.02% 88

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Perceptive Advisors's AXSM Position: Q2 2026 in Review

Perceptive Advisors reduced its Axsome Therapeutics (AXSM) stake by 21% in Q2 2026, selling an estimated $6.83M and leaving 118,450 shares worth $29M. The position accounts for 0.44% of the portfolio, ranked #47.

Perceptive Advisors first reported a position in AXSM in Q1 2019 and has held it in 20 quarters since. The position peaked at $88.2M in Q1 2024. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Perceptive Advisors held 118,450 shares of Axsome Therapeutics worth $29M as of Q2 2026.
  • Perceptive Advisors sold 31,500 Axsome Therapeutics shares in Q2 2026, an estimated $6.83M.
  • Axsome Therapeutics made up 0.44% of Perceptive Advisors's portfolio in Q2 2026, its #47 holding.
  • Perceptive Advisors first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 20 quarters since.
  • Perceptive Advisors's Axsome Therapeutics position peaked at $88.2M in Q1 2024.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.